4.5 Article

Combined central and peripheral demyelination: Clinical features, diagnostic findings, and treatment

Journal

JOURNAL OF THE NEUROLOGICAL SCIENCES
Volume 363, Issue -, Pages 182-187

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.jns.2016.02.022

Keywords

Combined central and peripheral demyelination; Chronic inflammatory demyelinating polyneuropathy; Multiple sclerosis; Acute disseminated encephalomyelitis; Guillain-Barre syndrome

Funding

  1. Italian Ministry of Health [120/RF-2011-02347955]

Ask authors/readers for more resources

Combined central and peripheral demyelination (CCPD) is rare, and current knowledge is based on case reports and small case series. The aim of our study was to describe the clinical features, diagnostic results, treatment and outcomes in a large cohort of patients with CCPD. Thirty-one patients entered this retrospective, observational, two-center study. In 20 patients (65%) CCPD presented, after an infection, as myeloradiculoneuropathy, encephalopathy, cranial neuropathy, length-dependent peripheral neuropathy, or pseudo-Guillain-Barre syndrome. Demyelinating features of peripheral nerve damage fulfilling European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) electrodiagnostic criteria for CIDP were found in 23 patients (74%), and spatial dissemination of demyelinating lesions on brain MRI fulfilling the 2010 McDonald criteria for multiple sclerosis (MS) in 11 (46%). Two thirds of the patients had a relapsing or progressive disease course, usually related to the appearance of new spinal cord lesions or worsening of the peripheral neuropathy, and showed unsatisfactory responses to high-dose corticosteroids and intravenous immunoglobulins. The clinical presentation of CCPD was severe in 22 patients (71%), who were left significantly disabled. Our data suggest that CCPD has heterogeneous features and shows frequent post-infectious onset, primary peripheral nervous system or central nervous system involvement, a monophasic or chronic disease course, inadequate response to treatments, and a generally poor outcome. We therefore conclude that the current diagnostic criteria for MS and CIDP may not fully encompass the spectrum of possible manifestations of CCPD, whose pathogenesis remains largely unknown. (C) 2016 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Biochemistry & Molecular Biology

Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial

David Adams, Ivailo L. Tournev, Mark S. Taylor, Teresa Coelho, Violaine Plante-Bordeneuve, John L. Berk, Alejandra Gonzalez-Duarte, Julian D. Gillmore, Soon-Chai Low, Yoshiki Sekijima, Laura Obici, Chongshu Chen, Prajakta Badri, Seth M. Arum, John Vest, Michael Polydefkis

Summary: This study assessed the effectiveness of vutrisiran in patients with hereditary transthyretin amyloidosis. The results showed significant improvements in disease-relevant outcomes and an acceptable safety profile for vutrisiran.

AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2023)

Article Clinical Neurology

Muscle quantitative MRI as a novel biomarker in hereditary transthyretin amyloidosis with polyneuropathy: a cross-sectional study

Elisa Vegezzi, Andrea Cortese, Niels Bergsland, Roberta Mussinelli, Matteo Paoletti, Francesca Solazzo, Riccardo Curro, Lucia Ascagni, Ilaria Callegari, Ilaria Quartesan, Alessandro Lozza, Xeni Deligianni, Francesco Santini, Enrico Marchioni, Giuseppe Cosentino, Enrico Alfonsi, Cristina Tassorelli, Stefano Bastianello, Giampaolo Merlini, Giovanni Palladini, Laura Obici, Anna Pichiecchio

Summary: This study investigates the role of muscle quantitative MRI (qMRI) as an outcome measure in hereditary transthyretin (ATTRv) amyloidosis. The researchers found that patients with ATTRv had significantly higher fat fraction (FF) and water T2 (wT2) values in their muscles compared to healthy controls. These qMRI biomarkers correlated with clinical and neurophysiological measures of disease severity.

JOURNAL OF NEUROLOGY (2023)

Article Clinical Neurology

Early Immunotherapy and Longer Corticosteroid Treatment Are Associated With Lower Risk of Relapsing Disease Course in Pediatric MOGAD

Margherita Nosadini, Michael Eyre, Thea Giacomini, Massimiliano Valeriani, Marida Della Corte, Andrea D. Pratico, Pietro Annovazzi, Ramona Cordani, Duccio Maria Cordelli, Giovanni Crichiutti, Gabriella Di Rosa, Valentina Dolcemascolo, Anna Fetta, Elena Freri, Paolo Gallo, Matteo Gastaldi, Tiziana Granata, Luisa Grazian, Raffaele Iorio, Martina Lombardini, Monica Margoni, Sara Mariotto, Sara Matricardi, Federico Melani, Nardo Nardocci, Laura Papetti, Alice Passarini, Francesco Pisani, Chiara Po, Marco Puthenparampil, Francesca Ragona, Salvatore Savasta, Sabrina Siliquini, Irene Toldo, Alessandra Tozzo, Emanuela Claudia Turco, Antonio Varone, Alberto Vogrig, Luigi Zuliani, Samuela Bugin, Sara Rossato, Alessandro Orsini, Gaetano Cantalupo, Maria Margherita Mancardi, Michela Ada Noris Ferilli, Thomas Foiadelli, Stefano Sartori

Summary: This study aimed to identify early factors associated with relapse and outcome in pediatric-onset MOGAD. The study found that early immunotherapy, longer duration of corticosteroid treatment, and abnormal optic nerves on MRI were associated with a lower risk of relapse. Meanwhile, higher disease severity at onset was associated with a greater risk of final disability.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2023)

Article Clinical Neurology

Telemedicine in Neuromuscular Diseases During Covid-19 Pandemic: ERN-NMD European Survey

Lynda El-Hassar, Ahmed Amara, Benoit Sanson, Oana Lacatus, Ahmed Amir Belhouchet, Madelon Kroneman, Kristl Claeys, Jean Philippe Plancon, Carmelo Rodolico, Guido Primiano, Francesca Trojsi, Massimiliano Filosto, Tiziana Enrica Mongini, Sara Bortolani, Mauro Monforte, Elena Carraro, Lorenzo Maggi, Federica Ricci, Vincenzo Silani, Daniele Orsucci, Alain Creange, Yann Pereon, Tanya Stojkovic, Nadine Anna Maria Elisabeth van der Beek, Antonio Toscano, Davide Pareyson, Shahram Attarian, Peter Y. K. Van den Bergh, Gauthier Remiche, Janneke G. J. Hoeijmakers, Umesh Badrising, Nicol C. Voermans, Angela M. Kaindl, Ulrike Schara-Schmidt, Benedikt Schoser, Elisabetta Gazzerro, Jana Haberlova, Stanislav Vohanka, Endre Pal, Maria Judit Molnar, Lea Leonardis, Ivailo L. Tournev, Andres Nascimento Osorio, Montse Olive, Nuria Muelas, Jorge Alonso-Perez, Francesc Pla, Marianne de Visser, Gabriele Siciliano, Sabrina Sacconi

Summary: Telemedicine has played a crucial role in providing healthcare assistance for NMD patients during the COVID-19 pandemic. However, there are limitations in its application, especially for patients with cognitive deficits or those in need of initial diagnosis. Therefore, it should be used as a complement rather than a substitute for face-to-face consultations.

JOURNAL OF NEUROMUSCULAR DISEASES (2023)

Review Clinical Neurology

Trials for Slowly Progressive Neurogenetic Diseases Need Surrogate Endpoints

Mary M. Reilly, David N. Herrmann, Davide Pareyson, Steven S. Scherer, Richard S. Finkel, Stephan Zuechner, Joshua Burns, Michael E. Shy

Summary: Heritable neurological disorders provide insights into disease mechanisms, facilitating the development of novel therapeutic approaches. The challenges of measuring disease progression in rare and slowly progressive neurogenetic diseases are addressed through the development of clinical outcome assessments and disease biomarkers in inherited peripheral neuropathies. It is proposed that carefully developed biomarkers from imaging, plasma, or skin can predict meaningful progression in functional and patient-reported outcome assessments, enabling feasible clinical trials within a shorter duration for these rare and ultra-rare disorders.

ANNALS OF NEUROLOGY (2023)

Article Clinical Neurology

Genetic analysis and natural history of Charcot-Marie-Tooth disease CMTX1 due to GJB1 variants

Christopher J. Record, Mariola Skorupinska, Matilde Laura, Alexander M. Rossor, Davide Pareyson, Chiara Pisciotta, Shawna M. E. Feely, Thomas E. Lloyd, Rita Horvath, Reza Sadjadi, David N. Herrmann, Jun Li, David Walk, Sabrina W. Yum, Richard A. Lewis, John Day, Joshua Burns, Richard S. Finkel, Mario A. Saporta, Sindhu Ramchandren, Michael D. Weiss, Gyula Acsadi, Vera Fridman, Francesco Muntoni, Roy Poh, James M. Polke, Stephan Zuchner, Michael E. Shy, Steven S. Scherer, Mary M. Reilly

Summary: This study collected demographic, clinical and genetic data on CMT patients with GJB1 variants and found that males are more severely affected than females. It also found that some reported GJB1 variants remain classified as variants of uncertain significance. By analyzing a large cohort, the study showed that enhanced variant interpretation increases the proportion of pathogenic variants in GJB1.

BRAIN (2023)

Article Clinical Neurology

Neuropathy due to bi-allelic SH3TC2 variants: genotype-phenotype correlation and natural history

Tyler Rehbein, Tong Tong Wu, Simona Treidler, Davide Pareyson, Richard Lewis, Sabrina W. Yum, Brett A. McCray, Sindhu Ramchandren, Joshua Burns, Jun Li, Richard S. Finkel, Steven S. Scherer, Stephan Zuchner, Michael E. Shy, Mary M. Reilly, David N. Herrmann

Summary: Recessive SH3TC2 variants cause CMT4C, a disease with variable clinical characteristics. Longitudinal analysis of 56 patients showed that CMTES and CMTES-R scores were moderately responsive to change over 3 years, indicating their usefulness in assessing disease progression.

BRAIN (2023)

Article Clinical Neurology

Clinical spectrum and frequency of Charcot-Marie-Tooth disease in Italy: Data from the National CMT Registry

Chiara Pisciotta, Alessandro Bertini, Irene Tramacere, Fiore Manganelli, Gian Maria Fabrizi, Angelo Schenone, Stefano Tozza, Tiziana Cavallaro, Federica Taioli, Moreno Ferrarini, Marina Grandis, Emilia Bellone, Paola C. Mandich, Stefano Previtali, Yuri Falzone, Isabella Allegri, Luca Padua, Costanza Pazzaglia, Aldo Quattrone, Paola Valentino, Luca Gentile, Massimo Russo, Daniela Calabrese, Isabella Moroni, Emanuela Pagliano, Paola Saveri, Stefania Magri, Silvia Baratta, Franco Taroni, Anna Mazzeo, Lucio Santoro, Giuseppe Vita, Davide Pareyson, Italian CMT Network

Summary: Data from the Italian CMT Registry show that 1012 patients were registered, with 535 females, and 711 patients received a genetic diagnosis. The most common mutation was the PMP22 duplication (45.2%). CMT4A was the most severe type, followed by CMT4C and CMT1E. Foot deformities and walking difficulties were the main features. Shoe inserts and orthotic aids were used by almost one-half of all patients. Scoliosis was present in 20% of patients, especially in CMT4C.

EUROPEAN JOURNAL OF NEUROLOGY (2023)

Article Clinical Neurology

Adult-onset leukodystrophy with vanishing white matter: a case series of 19 patients

Chiara Benzoni, Marco Moscatelli, Laura Farina, Stefania Magri, Claudia Ciano, Vidmer Scaioli, Sara Alvera, Gabriella Cammarata, Stefania Bianchi-Marzoli, Massimo Castellani, Felicia Margherita Zito, Giorgio Marotta, Sylvie Piacentini, Alberto Villacara, Renato Mantegazza, Cinzia Gellera, Joao Duraes, Ana Gouveia, Anabela Matos, Maria do Carmo Macario, Davide Pareyson, Franco Taroni, Daniela Di Bella, Ettore Salsano

Summary: In this study, clinical and laboratory information of adult-onset leukodystrophy with vanishing white matter (LVWM) patients was reviewed. The study found that AO-LVWM presents varying clinical manifestations, including stroke-like events; white matter rarefaction is the most consistent diagnostic clue; cerebral glucose metabolic abnormalities and retinal alterations can be present; and LVWM might also be caused by a digenic inheritance affecting the eIF2B complex.

JOURNAL OF NEUROLOGY (2023)

Article Clinical Neurology

Magnetic resonance neurography and diffusion tensor imaging of the sciatic nerve in hereditary transthyretin amyloidosis polyneuropathy

Roberto Gasparotti, Alessandro Salvalaggio, Daniele Corbo, Giorgio Agazzi, Mario Cacciavillani, Alessandro Lozza, Silvia Fenu, Grazia De Vigili, Matteo Tagliapietra, Gian Maria Fabrizi, Davide Pareyson, Laura Obici, Chiara Briani

Summary: Quantitative assessment of Magnetic Resonance Neurography (MRN) and Diffusion Tensor Imaging (DTI) of the sciatic nerve can reliably differentiate hereditary transthyretin amyloidosis (ATTRv) patients and pre-symptomatic carriers, providing a potential tool for early diagnosis and disease monitoring.

JOURNAL OF NEUROLOGY (2023)

Letter Clinical Neurology

Recruiting for an International Rare Disease Clinical Trial Readiness Study during the COVID-19 pandemic: Challenges and solutions

Katy Eichinger, Steffen E. Behrens-Spraggins, Janet Sowden, Davide M. Pareyson, Mary S. Reilly, Steven E. Scherer, Michael N. Shy, David Herrmann

JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM (2023)

Article Clinical Neurology

Complex Ataxia-Dementia Phenotype in Patients with Digenic TBP/STUB1 Spinocerebellar Ataxia

Lorenzo Nanetti, Stefania Magri, Mario Fichera, Anna Castaldo, Anna Nigri, Chiara Pinardi, Alessia Mongelli, Lidia Sarro, Davide Pareyson, Marina Grisoli, Cinzia Gellera, Daniela Di Bella, Caterina Mariotti, Franco Taroni

Summary: This study identified a form of spinocerebellar ataxia (SCA) characterized by the presence of an intermediate-length expansion in the TATA-box binding protein gene (TBP40-46) and a pathogenic variant in the Stip1-homologous and U-Box containing protein 1 gene (STUB1), representing the first example of digenic inheritance in a cerebellar disorder. Patients with SCA(TBP/STUB1) exhibited multi-domain dementia and more severe impairment compared to those carrying only fully expanded SCA17 alleles. Neuroimaging analysis revealed reduced cerebellar volume and thickness in SCA(TBP/STUB1) patients, as well as basal ganglia volume reduction in both patient groups. The findings have implications for diagnosis and genetic counseling in families with hereditary and sporadic ataxia.

MOVEMENT DISORDERS (2023)

Editorial Material Clinical Neurology

Serum MOG-IgG titers should be performed routinely in the diagnosis and follow-up of MOGAD: Commentary

Matteo Gastaldi, Diego Franciotta

MULTIPLE SCLEROSIS JOURNAL (2023)

Article Oncology

Late-onset vascular complications of radiotherapy for primary brain tumors: a case-control and cross-sectional analysis

Maria-Jose Ibanez-Julia, Alberto Picca, Delphine Leclercq, Giulia Berzero, Julian Jacob, Loic Feuvret, Charlotte Rosso, Cristina Birzu, Agusti Alentorn, Marc Sanson, Camille Tafani, Flavie Bompaire, Luis Bataller, Khe Hoang-Xuan, Jean-Yves Delattre, Dimitri Psimaras, Damien Ricard

Summary: It has been found that there is an increased risk of stroke in adults with primary brain tumors who have undergone cranial radiotherapy.

JOURNAL OF CANCER SURVIVORSHIP (2023)

Article Clinical Neurology

Daytime sleepiness and sleep quality in Charcot-Marie-Tooth disease

Marta Bellofatto, Luca Gentile, Alessandro Bertini, Irene Tramacere, Fiore Manganelli, Gian Maria Fabrizi, Angelo Schenone, Lucio Santoro, Tiziana Cavallaro, Marina Grandis, Stefano Previtali, Marina Scarlato, Isabella Allegri, Luca Padua, Costanza Pazzaglia, Flavio Villani, Eleonora Cavalca, Paola Saveri, Aldo Quattrone, Paola Valentino, Stefano Tozza, Massimo Russo, Anna Mazzeo, Giuseppe Vita, Sylvie Piacentini, Giuseppe Didato, Chiara Pisciotta, Davide Pareyson, CMT Network

Summary: This study investigated the presence of sleep abnormalities in Charcot-Marie-Tooth disease (CMT) patients and their correlation with disease severity and characteristics. The results showed that CMT patients had poor sleep quality and daytime somnolence, which were associated with anxiety, depression, and fatigue.

JOURNAL OF NEUROLOGY (2023)

No Data Available